In short
Clinical trials are studying INDAPAMIDE HEMIHYDRATE in people with chronic post-surgical hypoparathyroidism. These studies are looking mainly at whether treatment can change urinary calcium levels and how well it works compared with placebo. The trial data here include adults in a Phase 3 interventional study.
Key points
- Clinical trials of INDAPAMIDE HEMIHYDRATE in the provided data are focused on chronic post-surgical hypoparathyroidism. The main study is a Phase 3 interventional trial called HYPOCARE TREAT. It compares INDAPAMIDE HEMIHYDRATE with placebo tablets. Researchers are measuring changes in 24-hour urinary calcium excretion after 7 days and 14 days. The trial is authorised and plans to include 24 participants.
Trial overview
The available trial data describe one interventional study of INDAPAMIDE HEMIHYDRATE called HYPOCARE TREAT. It is studying people with chronic post-surgical hypoparathyroidism.
This study is in Phase 3, which means it is a later-stage clinical trial that looks at how well the treatment works in people with the condition.
Who is being studied
The target population is patients with chronic post-surgical hypoparathyroidism. “Post-surgical” means the condition happened after surgery, and “chronic” means it is long-lasting.
The source data do not list more details about age, sex, or other entry rules.
Study design and treatment groups
HYPOCARE TREAT is an interventional trial, so researchers are giving a study treatment and comparing results. The study compares daily INDAPAMIDE HEMIHYDRATE with placebo tablets.
The brief summary says patients receive daily treatment for 14 days, and the comparison is made against placebo.
What the trial measures
The main outcome is 24-hour urinary calcium excretion, which means the amount of calcium passed in urine over one full day. Researchers are checking how this changes after 7 days and after 14 days of treatment.
This endpoint helps show whether the study treatment changes calcium loss in urine in people with chronic post-surgical hypoparathyroidism.
Trial status and size
The study status is Authorised, which means it has been approved to run. The planned enrollment is 24 participants, so this is a small trial.
Key terms explained
Placebo means a tablet that looks like the study medicine but does not contain the active treatment. Researchers use it to compare results fairly.
Endpoint means the main result the researchers measure in the trial. In this study, the endpoint is the change in urinary calcium over time.
Enrollment is the number of people planned for the trial. Here, the planned enrollment is 24 people.